US Supreme Court Struggles With Post-Sale Patent Questions
Executive Summary
During oral argument in Helsinn v. Teva, several justices seemed skeptical of making a distinction between public and private sales of an invention in assessing its patentability.
You may also be interested in...
Sale of Invention May Block Its Patenting Even If Details Are Not Disclosed, Supreme Court Concludes
America Invents Act did not alter the meaning of "on sale," unanimous court finds, so a confidential sale can qualify as prior art.
Brand Vs. Generic Supreme Court Fight: Does Sale Of Secret Invention Bar Its Patenting?
In case with potentially broad ramifications for biopharma partnerships, high court will hear arguments Dec. 4 on whether America Invents Act changed the "on-sale bar" to patentability to allow inventions that are sold to be patented if their details are not publicly disclosed.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.